Marinus Pharmaceuticals, Inc. financial data

Symbol
MRNS on Nasdaq
Industry
Pharmaceutical Preparations
Location
5 Radnor Corporate Center Suite 500, 100 Matsonford Rd, Radnor, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 283 % -66.2%
Quick Ratio 12.9 % +139%
Debt-to-equity -503 % -374%
Return On Equity 494 %
Return On Assets -122 % -103%
Operating Margin -396 % +2.14%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.2M shares +1.12%
Common Stock, Shares, Outstanding 55.2M shares +1.12%
Entity Public Float 545M USD +204%
Common Stock, Value, Issued 55K USD 0%
Weighted Average Number of Shares Outstanding, Basic 57.2M shares +6.14%
Weighted Average Number of Shares Outstanding, Diluted 57.2M shares +6.14%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 31.5M USD +1.63%
Revenue from Contract with Customer, Excluding Assessed Tax 12.7M USD
Research and Development Expense 87.7M USD -7.09%
General and Administrative Expense 48.9M USD +76%
Costs and Expenses 156M USD -0.12%
Operating Income (Loss) -125M USD +0.55%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -24.2M USD +26.5%
Income Tax Expense (Benefit) -1.54M USD
Net Income (Loss) Attributable to Parent -140M USD -4.89%
Earnings Per Share, Basic -2.47 USD/shares +10.2%
Earnings Per Share, Diluted -2.47 USD/shares +8.86%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.2M USD -70%
Cash, Cash Equivalents, and Short-term Investments 113M USD
Accounts Receivable, after Allowance for Credit Loss, Current 3.84M USD -10.3%
Inventory, Net 6.72M USD +146%
Assets, Current 57.4M USD -70.6%
Property, Plant and Equipment, Net 4.88M USD +24.9%
Operating Lease, Right-of-Use Asset 500K USD -50%
Other Assets, Noncurrent 1.34M USD -27.8%
Assets 63.6M USD -68.3%
Accounts Payable, Current 3.71M USD +41.2%
Employee-related Liabilities, Current 2.13M USD -70.3%
Accrued Liabilities, Current 14.2M USD -22.7%
Liabilities, Current 34.5M USD +12.9%
Operating Lease, Liability, Noncurrent 211K USD -78.7%
Liabilities 130M USD -10.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -20K USD
Retained Earnings (Accumulated Deficit) -671M USD -26.5%
Stockholders' Equity Attributable to Parent -66.7M USD -222%
Liabilities and Equity 63.6M USD -68.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.5M USD +9.69%
Net Cash Provided by (Used in) Financing Activities 257K USD
Net Cash Provided by (Used in) Investing Activities 20.9M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 55.2M shares +1.12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.3M USD +82.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.2M USD -70%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2.67M USD +23.9%
Deferred Tax Assets, Valuation Allowance 167M USD +35.4%
Deferred Tax Assets, Gross 168M USD +35.4%
Operating Lease, Liability 804K USD -46.7%
Depreciation 131K USD -16.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -140M USD -4.78%
Lessee, Operating Lease, Liability, to be Paid 853K USD -49.5%
Property, Plant and Equipment, Gross 5.74M USD +0.93%
Operating Lease, Liability, Current 804K USD +14.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 662K USD -21.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 642K USD -23.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 49K USD -72.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 642K USD -23.6%
Deferred Tax Assets, Operating Loss Carryforwards 72.8M USD +25.4%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 604M USD +3.27%
Share-based Payment Arrangement, Expense 18.9M USD +19.9%
Interest Expense 17.1M USD +30.2%